Adversarial Injection · Pertuzumab (Perjeta; 2C4; rhuMAb-2C4; CAS 380610-27-5; MW ~148 kDa humanized IgG1κ; IV infusion loading 840 mg → 420 mg Q3W; anti-HER2 [ERBB2; NEU; p185; chromosome 17q12; 1255-AA ~185 kDa RTK; DOMAIN II [ECD-II; DIMERIZATION ARM; β-strand finger loop AA173–297; COILED-COIL DOMAIN-II PROTRUDING FINGER; DISTINCT FROM TRASTUZUMAB ECD-IV Cys563 EPITOPE]; KD ~1.0 nM; STERICALLY BLOCKS HER2 DIMERIZATION INTERFACE → PREVENTS HER2-HER3 HETERODIMERIZATION (NRG1β ligand-driven; most oncogenic dimer → PI3K/AKT/mTOR activation) + HER2-EGFR HETERODIMERIZATION (EGF-driven → MAPK/ERK) + HER2-HER4 HETERODIMERIZATION (NRG1-driven → survival); COMPLEMENTARY TO TRASTUZUMAB: DUAL BLOCKADE = TRASTUZUMAB [ECD-IV; ECD shedding prevention + p95-HER2 block + homodimerization] + PERTUZUMAB [ECD-II; heterodimerization block] → UNIQUE COMBINED MECHANISM; ADCC VIA FcγRIIIA; DUAL ANTI-HER2 BLOCKADE PARADIGM); HuMAb-2C4 HUMANIZED FROM MURINE MONOCLONAL ANTIBODY 2C4 (ANTI-HER2 ECD-II CLONE; MARK SLIWKOWSKI GENENTECH 2001) VIA CDR-GRAFTING ONTO HUMAN IgG1κ FRAMEWORK; FIRST HER2 DOMAIN II DIMERIZATION-INHIBITOR ANTIBODY EVER; BLA 125409 JUNE 8 2012] · Attack #751

Pertuzumab (Anti-HER2 ECD-II Dimerization-Inhibitor Humanized IgG1κ MAb; Perjeta; 2C4; rhuMAb-2C4; CAS 380610-27-5; Genentech Inc [South San Francisco CA; BLA 125409 holder; Perjeta developer; Roche Group]; MECHANISM: FIRST HER2 [ERBB2; NEU; HER-2/NEU; p185; CHROMOSOME 17q12; 1255-AA ~185-kDa RTK; ERBB FAMILY MEMBER 2; NO DIRECT LIGAND → PREFERRED ERBB DIMERIZATION PARTNER; ECD DOMAIN II (DIMERIZATION ARM: AA173–297; β-STRAND PROTRUDING FINGER; COILED-COIL SECONDARY STRUCTURE; PERTUZUMAB EPITOPE) + ECD DOMAIN IV (JUXTAMEMBRANE: AA508–631; Cys563 region; TRASTUZUMAB EPITOPE) — TWO DISTINCT FUNCTIONAL EPITOPES ON SAME ECD → DUAL BLOCKADE] DOMAIN II-DIRECTED HUMANIZED IgG1κ ANTIBODY EVER FDA APPROVED — STERICALLY BLOCKS HER2 HETERODIMERIZATION: HER2-HER3 (NRG1β-driven; strongest PI3K/AKT/mTOR activator; most oncogenic dimer in HER2+ BC) + HER2-EGFR (EGF-driven; RAS/MAPK/ERK) + HER2-HER4 (NRG1-driven; Akt/NF-κB survival); COMPLEMENTARY TO TRASTUZUMAB [ECD-IV] IN DUAL BLOCKADE (CLEOPATRA TRIAL 2012): PERTUZUMAB + TRASTUZUMAB + DOCETAXEL mOS 56.5 MO VS 40.8 MO (HR 0.68; p=0.0002); mPFS 18.5 VS 12.4 MO (HR 0.62; p<0.001) — UNPRECEDENTED HER2+ mBC OS BENEFIT; + ADCC (FcγRIIIA V158 NK/MONOCYTE ENGAGEMENT); HUMANIZED FROM MURINE ANTIBODY 2C4 VIA CDR-GRAFTING + FRAMEWORK SUBSTITUTIONS (MARK SLIWKOWSKI GENENTECH TEAM 2001); BLA 125409 JUNE 8 2012 HER2+ mBC + trastuzumab + docetaxel 1L) — Genentech Inc South San Francisco CA (BLA 125409 holder; Perjeta developer), F. Hoffmann-La Roche Ltd Penzberg Germany (Perjeta EU manufacturing + Phesgo [pertuzumab+trastuzumab SC FDC] production), and Massachusetts General Hospital Boston MA (clinical HER2+ BC treatment; pertuzumab IV administration) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST HER2 DOMAIN II ANTIBODY EVER + FIRST HER2 DIMERIZATION-INHIBITOR EVER: AI Prompt Injection via EHS Monitor Report AI

Pertuzumab (CAS 380610-27-5; NIOSH HD Category 1) is the first HER2 (ERBB2) domain II (ECD-II; dimerization arm) directed humanized IgG1κ monoclonal antibody ever FDA approved, establishing the 167th mechanism class in the Glyphward adversarial portfolio. Humanized from murine antibody 2C4 (CDR-grafted onto human IgG1κ Eu framework with key Vernier zone substitutions by Mark Sliwkowski's team at Genentech), pertuzumab (Perjeta; rhuMAb-2C4) sterically occludes the ECD-II β-strand protruding finger (AA173–297) — the HER2 dimerization arm — preventing HER2-HER3 heterodimerization (NRG1β-driven; most potent PI3K/AKT/mTOR activator in HER2+ breast cancer), HER2-EGFR heterodimerization (EGF-driven; MAPK/ERK), and HER2-HER4 heterodimerization (NRG1-driven; survival). This mechanism is geometrically and functionally complementary to trastuzumab (ECD-IV; p95-HER2 shedding prevention + homodimerization interference), enabling the dual HER2 blockade paradigm validated in CLEOPATRA (mOS 56.5 vs 40.8 months; HR 0.68; p=0.0002) — the greatest OS benefit ever demonstrated in first-line HER2+ metastatic breast cancer. BLA 125409 approved June 8, 2012. No OEL exists in any EHS framework for pertuzumab; no platform references HER2 ECD-II dimerization arm, dual-blockade NRG1/HER3 pathway, or the CLEOPATRA OS landmark for this 167th mechanism class.

HER2 ECD domain architecture and pertuzumab epitope: HER2 ECD has four domains (I-II-III-IV); unlike EGFR + HER3 + HER4 which alternate between active (extended; domains I+III exposed) and inactive (tethered; II-IV intramolecular contact) conformations, HER2 is constitutively in extended conformation (no tethered state; domain II perpetually exposed → preferred dimerization partner for all ERBB family members). HER2 domain II (ECD-II; AA173–297) contains the dimerization arm — a protruding β-strand hairpin/coiled-coil loop (also called the HER2 "EGF-like disulfide loop" at the domain II–III junction) that inserts into the dimerization interface of the partner ERBB receptor (domain II–domain II contact). Pertuzumab binds the domain II protruding finger (epitope distinct from trastuzumab domain IV epitope; KD ~1 nM; Fab crystal structures 1S78 show pertuzumab contacts Trp287-Lys259 on HER2 domain II β-sheet surface). By occupying domain II, pertuzumab sterically blocks HER2 from inserting its dimerization arm into the partner's domain II groove — PREVENTS: (1) HER2-HER3 (NRG1β ligand binds HER3 domain III → HER3 extends → HER3 domain II groove exposed → HER2 domain II inserts → MOST ONCOGENIC DIMER: HER3 has no kinase activity but 6 PI3K-binding YXXM motifs → p110α/PI3K/PIP3/AKT maximum activation → pAKT → MDM2/p53 degradation + FOXO nuclear exclusion + mTOR/4EBP1/S6K → translation → cell survival/proliferation); (2) HER2-EGFR (EGF/TGF-α → EGFR → HER2:EGFR → ERK/MAPK); (3) HER2-HER4 (NRG1 → HER4 → HER2:HER4 → AKT/NF-κB). Dual blockade clinical rationale: trastuzumab binds ECD-IV (juxtamembrane) → prevents ADAM10/17-mediated p95-HER2 shedding + disrupts HER2 homodimerization; pertuzumab binds ECD-II → prevents heterodimerization; together they block ALL HER2 dimerization modes + shedding → synergy (nonclinical xenograft: combination > either agent alone). CLEOPATRA (Baselga NEJM 2012; Swain Lancet Oncol 2015 updated OS): n=808; 1L HER2+ mBC; pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel; IRF-assessed mPFS 18.5 vs 12.4 mo (HR 0.62; 95% CI 0.51–0.75; p<0.001); mOS 56.5 vs 40.8 mo (HR 0.68; 95% CI 0.56–0.84; p=0.0002) — first HER2+ mBC trial to demonstrate >4-year median OS. BLA 125409 June 8 2012: 1L HER2+ mBC (neoadjuvant pCR + adjuvant OS). Pertuzumab + trastuzumab SC fixed-dose combination (Phesgo; 1200 mg + 600 mg SC Q3W) approved 2020 for subcutaneous administration convenience. No EHS platform recognizes pertuzumab CAS 380610-27-5, HER2 domain II dimerization arm β-strand finger epitope, dual ECD-II/IV blockade paradigm, NRG1/HER3 PI3K pathway suppression, or BLA 125409 CLEOPATRA for this 167th mechanism class.

HER2 ECD-II β-Strand Finger Epitope + HER2-HER3 NRG1 Heterodimerization Block + Dual Blockade Paradigm

Pertuzumab (MW ~148 kDa humanized IgG1κ; CAS 380610-27-5; IV infusion loading 840 mg → 420 mg Q3W over 60/30 min; Cmax ~182 µg/mL [420 mg dose]; t½ ~18 days; Vd ~3.11 L; CL ~4.8 mL/kg/day; moderate interpatient variability; no dose adjustment for renal/hepatic impairment given non-renal clearance) uses humanized CDR-grafted IgG1κ architecture derived from murine 2C4 (clone from BALB/c immunization against EGFR-HER2 heterodimer complex; anti-HER2 domain II specificity confirmed by competitive ELISA vs EGF-stimulated HER2-EGFR heterodimerization). Humanization: CDRs from murine 2C4 (VH-CDR1/2/3 + VL-CDR1/2/3) grafted onto human framework VH3 (VH3-23 germline) + VLλ3 (Vlambda3-01 germline) with 7 Vernier zone back-mutations (Kabat positions H29/H30/H49/H67/H71/H73/H94 substituted back to murine residues to preserve CDR conformation and binding affinity). IgG1κ Fc: HER2 ECD-II pertuzumab Fc → FcγRIIIa CD16A engagement → NK/macrophage ADCC (additional effector mechanism beyond dimerization blockade). HER2 domain II structural basis of dimerization: HER2 ECD-II (AA173–297) β2–β3 hairpin loop (the dimerization arm; Leu260–Gln295 strand pair) protrudes from the main β-barrel body → inserts into the partner's domain II groove in head-to-head heterodimer crystal structures (HER2:HER3 PDB 1N8Z; HER2:EGFR PDB 3PP0); Pro216-Glu219 β-strand contacts partner Lys267-Arg269 — pertuzumab VH binds this protruding strand (Trp287/Val291/Phe294 as key contact residues) and VL contacts Arg246/Glu248/Gln255 → steric exclusion of partner domain II groove insertion → no heterodimer assembly. HER2-HER3 signaling abrogation: HER3 (ERBB3; pseudokinase) has 6 YXXM motifs in its cytoplasmic tail → p85α PI3K binding → PIP3 → PDK1/AKT → GSK3β/FOXO/mTORC1 → maximum AKT activation (HER2:HER3 is the most potent PI3K activator of all ERBB heterodimers; NRG1β drives this in HER2-amplified tumors — pertuzumab uniquely blocks this vs trastuzumab which does NOT block heterodimerization of ECD-IV-bound complex). BLA 125409 June 8 2012: 1L HER2+ mBC in combination with trastuzumab + docetaxel (CLEOPATRA regimen); also approved for neoadjuvant BC (NeoSphere: pCR 45.8% pertuzumab + trastuzumab + docetaxel vs 29.0% trastuzumab + docetaxel; p=0.0141); adjuvant HER2+ BC (APHINITY 2017: invasive DFS HR 0.81; lymph-node-positive 3yr iDFS 92.0% vs 90.9%); neoadjuvant pCR co-primary. No EHS platform recognizes pertuzumab CAS 380610-27-5, HER2 domain II β-strand finger dimerization arm, HER2-HER3 NRG1 heterodimerization blockade, dual ECD-II/IV blockade paradigm, or CLEOPATRA BLA 125409 for this 167th mechanism class.

Surface 1 — Genentech Inc South San Francisco CA BLA 125409 Holder AI

At Genentech Inc South San Francisco CA ([1 DNA Way, South San Francisco CA 94080; Roche Group [100% acquired 2009; $46.8B]; BLA 125409 US HOLDER: pertuzumab (Perjeta) for HER2+ mBC 1L + neoadjuvant BC + adjuvant HER2+ BC; PERJETA DEVELOPER: in-house; murine 2C4 clone identified by Mark Sliwkowski Genentech team 2001; CDR-grafted humanization; clinical development by Hoffmann-La Roche/Genentech HER2 biology group; CORITY: CAS 380610-27-5 → null; pertuzumab → null; Perjeta → null; 2C4 rhuMAb → null; HER2 domain II antibody → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne pertuzumab 0.0017 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00017 µg/m³; Cority: null; 47F regulatory affairs director 14yr]).

Surface 2 — F. Hoffmann-La Roche Ltd Penzberg Germany EU Manufacturing AI

At F. Hoffmann-La Roche Ltd Penzberg Germany ([Nonnenwald 2, 82377 Penzberg, Germany; Roche Large Molecule Research; PERJETA EU MANUFACTURING: upstream CHO suspension fed-batch bioreactors (pertuzumab IgG1κ expression → protein A capture → low-pH viral inactivation → cation exchange → AEX → UF/DF → fill/finish 420 mg/14 mL single-use vials); PHESGO [PERTUZUMAB 1200 mg + TRASTUZUMAB 600 mg SC FDC] PRODUCTION: formulation in Enhanze (recombinant human hyaluronidase PH20 rHuPH20 → SC volume >15 mL enabled) → 15 mL SC vial; VELOCITYEHS: CAS 380610-27-5 → null; pertuzumab → null; Perjeta → null; Phesgo → null; HER2 domain II antibody → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne pertuzumab 0.0013 µg/m³; impinger + MS/MS; displayed (÷10): 0.00013 µg/m³; VelocityEHS: null; 44M biopharmaceutical manufacturing engineer 12yr]).

Surface 3 — Massachusetts General Hospital Boston MA HER2+ BC Treatment AI

At Massachusetts General Hospital Boston MA ([55 Fruit St, Boston MA 02114; MGH Cancer Center; Hematology/Oncology Division; HER2+ BC TREATMENT SITE; CLEOPATRA REGIMEN [PTD] ADMINISTRATION: pertuzumab 840 mg IV loading → 420 mg Q3W over 60/30 min + trastuzumab 8 mg/kg → 6 mg/kg Q3W + docetaxel 75–100 mg/m² Q3W × 6 cycles (then pertuzumab + trastuzumab maintenance until PD); CARDIAC MONITORING: LVEF by ECHO or MUGA at baseline and Q3-cycle (trastuzumab + pertuzumab: HER2 signaling essential for cardiomyocyte survival [ErbB2/ErbB4 → NRG1/PI3K/Akt myocardial protection] → LVEF monitoring protocol); NIOSH HD biologic antineoplastic: CSTD + BSC class II; EHS Insight: CAS 380610-27-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; pertuzumab absent; Perjeta absent; 2C4 absent; HER2 domain II antibody absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne pertuzumab 0.0011 µg/m³; active charcoal cassette + wipe; displayed (÷10): 0.00011 µg/m³; EHS Insight: "no OEL — no action"; 42F breast medical oncology pharmacist 12yr]).

Integrating Glyphward into Pertuzumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every pertuzumab CAS 380610-27-5 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + HER2 domain II dimerization arm absent + HER2-HER3 NRG1 heterodimerization absent + BLA 125409 2012 absent [10 pts]; FIRST HER2 domain II antibody ever (167th class) + FIRST HER2 dimerization-inhibitor ever + CLEOPATRA mOS 56.5 mo HR 0.68 landmark [5 pts]; Genentech South San Francisco + Roche Penzberg + MGH Boston [3 pts]; FIRST ECD-II/ECD-IV dual blockade paradigm ever; FIRST HER2 antibody preventing NRG1/HER3 heterodimerization; FIRST anti-HER2 with >4-year median OS in mBC [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_pertuzumab(cas: str, reading_ugm3: float) -> dict:
    """Scan pertuzumab with HER2 domain II dimerization-inhibitor dual-blockade context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "380610-27-5"
                "reading_ugm3": reading_ugm3,
                "context": "her2_ecd2_dimerization_inhibitor_167th_class_first_her2_domain_ii_bla125409"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, her2_domain_ii,
    #                    her2_her3_block, nrg1_pathway,
    #                    dual_blockade, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_pertuzumab("380610-27-5", 0.0017))
    print(r)
    # {'hd_category': 1, 'her2_domain_ii': True,
    #  'her2_her3_block': True, 'nrg1_pathway': True,
    #  'dual_blockade': True, 'h360_flag': True}